Skip to main content

Table 1 Demographic characteristics of ICU-admitted patients treated with two different formulations of intravenous colistina

From: Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study

 

Overall patients

Intravenous colistin

P-value

Locolin®

Colimycin®

No. of patients

195

95

100

 

Age, years (SD)

73.8 (13.5)

75.2 (12.3)

72.4 (14.6)

0.142

Sex

0.069

Male

138 (70.8%)

73 (76.8%)

65 (65%)

 

Female

57 (29.2%)

22 (23.2%)

35 (35%)

 

BMI (SD)

22.3 (4.6)

21.7 (4.8)

22.8 (4.3)

0.106

Smoking

78 (40%)

40 (42.1%)

38 (38%)

0.559

Comorbidities

 

Diabetes

57 (29.2%)

28 (29.5%)

29 (29%)

0.942

Malignancies

33 (16.9%)

24 (25.3%)

9 (9%)

0.002

Renal insufficiency (CCr < 30)

21 (10.8%)

10 (10.5%)

11 (11%)

0.915

Chronic liver diseases

16 (8.2%)

3 (3.2%)

13 (13%)

0.017

Heart failure

17 (8.7%)

8 (8.4%)

9 (9%)

0.886

CR-GNB culture sources

 

Respiratory specimens

157 (80.5%)

75 (78.9%)

82 (82%)

0.591

Urine

11 (5.6%)

6 (6.3%)

5 (5%)

0.691

Blood

10 (5.1%)

4 (4.2%)

6 (6%)

0.571

Others

17 (8.7%)

10 (10.5%)

7 (7%)

0.383

CR-GNB species

 

CRAB

141 (72.3%)

64 (67.4%)

77 (77%)

0.270

CRE

45 (23.1%)

28 (29.5%)

17 (17%)

0.051

CRPA

9 (4.6%)

3 (3.2%)

6 (6%)

0.344

Laboratory results (Mean, SD)

 

Leukocytes (× 109 per L)

13.2 (9.0)

13.2 (8.3)

13.3 (9.7)

0.935

CRP (mg/dL)

10.0 (6.5)

10.3 (7.6)

9.6 (5.9)

0.464

Albumin level (median, IQR)

2.7 (2.4–3.0)

2.8 (2.5–3.1)

2.6 (2.3–2.9)

0.017

Concomitant nephrotoxins

 

Aminoglycoside

22 (11.3%)

15 (15.8%)

7 (7%)

0.052

Vancomycin

20 (10.3%)

13 (13.7%)

7 (7%)

0.124

Intravenous contrast agent

39 (20.0%)

17 (17.9%)

22 (22%)

0.474

Disease severity

 

APACHEII scores (median, IQR)b

24 (19–30)

25 (20–30)

24 (19–30)

0.768

Respiratory failured

175 (89.7%)

83 (87.4%)

92 (92%)

0.287

Septic shockd

61 (31.3%)

33 (34.7%)

28 (28%)

0.310

Intravenous colistin

 

Daily dosage (MIU) (median, IQR)

8 (4–10)

8 (4–10)

8 (4–10)

0.814

Treatment duration (median, IQR)

7 (4–12)

7 (4–12)

7 (4–12)

0.782

Accumulated dosage (MIU) (median, IQR)

48 (28–80)

48 (28–64)

48 (24–88)

0.956

Inappropriate colistin dosage

23 (11.8%)

7 (7.4%)

16 (16%)

0.062

  1. APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, ICU intensive care unit, IQR interquartile range, CCr creatinine clearance, CR-GNB carbapenem-resistant gram-negative bacteria, SD standard deviation
  2. aData are presented as n (%)
  3. bIncluding abscess, ascites, CSF, and pericardial effusion
  4. cEvaluated on the day of ICU admission
  5. dPresent on the day of sample collection
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us